Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Mizuho Analyst Says

Insmed (NASDAQ:INSM) had its price objective lifted by equities research analysts at Mizuho from $96.00 to $110.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s price target points to a potential upside of 13.54% from the company’s current price.

INSM has been the subject of a number of other research reports. Morgan Stanley lifted their target price on shares of Insmed from $90.00 to $102.00 and gave the company an “overweight” rating in a research note on Wednesday. Guggenheim reissued a “buy” rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Citigroup raised Insmed to a “buy” rating in a research report on Tuesday. Jefferies Financial Group reaffirmed a “buy” rating on shares of Insmed in a research note on Tuesday. Finally, Truist Financial boosted their price target on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $104.81.

Insmed Trading Down 1.1%

Shares of NASDAQ INSM opened at $96.88 on Wednesday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed has a one year low of $60.40 and a one year high of $100.00. The business has a 50-day moving average price of $70.73 and a two-hundred day moving average price of $73.47. The firm has a market capitalization of $17.65 billion, a PE ratio of -17.33 and a beta of 0.80.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. During the same period last year, the company earned ($1.06) earnings per share. Insmed’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, analysts predict that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO William Lewis sold 6,830 shares of the firm’s stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the transaction, the chief executive officer now directly owns 233,924 shares in the company, valued at approximately $16,412,107.84. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of Insmed stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider now owns 89,407 shares in the company, valued at $8,352,401.94. This trade represents a 52.59% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 262,166 shares of company stock worth $20,585,587. 3.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insmed

Hedge funds have recently bought and sold shares of the company. Strs Ohio bought a new position in shares of Insmed in the first quarter worth about $1,961,000. Intech Investment Management LLC grew its holdings in Insmed by 43.2% in the 1st quarter. Intech Investment Management LLC now owns 101,979 shares of the biopharmaceutical company’s stock valued at $7,780,000 after buying an additional 30,752 shares during the last quarter. Bayforest Capital Ltd increased its position in Insmed by 255.0% in the 1st quarter. Bayforest Capital Ltd now owns 7,054 shares of the biopharmaceutical company’s stock worth $538,000 after buying an additional 5,067 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Insmed by 10.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 539,484 shares of the biopharmaceutical company’s stock worth $41,157,000 after buying an additional 52,637 shares during the period. Finally, Woodline Partners LP lifted its holdings in shares of Insmed by 53.3% during the first quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company’s stock worth $18,979,000 after buying an additional 86,540 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.